ArticleEClinicalMedicine2024

Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial.

Ruixi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.